Intra-Cellular Therapies, Inc.
NASDAQ: ITCI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Sharon Mates
- Employees
- 860
- Headquarters
- New York City, United States
- IPO year
- 2014
- Market cap
- $14.0B
- Website
- https://www.intracellulartherapies.com
Loading ITCI…
Loading profile data…Frequently asked questions about ITCI
What does Intra-Cellular Therapies, Inc. (ITCI) do?
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product...
Where does ITCI trade?
Intra-Cellular Therapies, Inc. (ITCI) trades on the NASDAQ Global Select.
What sector is ITCI in?
Intra-Cellular Therapies, Inc. (ITCI) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Intra-Cellular Therapies, Inc.?
Sharon Mates is the chief executive officer of Intra-Cellular Therapies, Inc. (ITCI).
Where is Intra-Cellular Therapies, Inc. headquartered?
Intra-Cellular Therapies, Inc. is headquartered in United States.
Does ITCI pay a dividend?
Intra-Cellular Therapies, Inc. (ITCI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ITCI go public?
Intra-Cellular Therapies, Inc. (ITCI) completed its initial public offering in 2014.